You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Novo Nordisk Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Novo Nordisk Inc
International Patents:83
US Patents:4
Tradenames:4
Ingredients:3
NDAs:4
Drug Master File Entries: 3
Patent Litigation for Novo Nordisk Inc: See patent lawsuits for Novo Nordisk Inc

Drugs and US Patents for Novo Nordisk Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novo Nordisk Inc INNOFEM estradiol TABLET;ORAL 040312-003 Nov 19, 1999 DISCN No No ⤷  Try for Free ⤷  Try for Free
Novo Nordisk Inc INNOFEM estradiol TABLET;ORAL 040312-001 Nov 19, 1999 DISCN No No ⤷  Try for Free ⤷  Try for Free
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 AP RX Yes Yes 7,762,994*PED ⤷  Try for Free Y ⤷  Try for Free
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-002 Nov 25, 2009 AB RX Yes Yes ⤷  Try for Free ⤷  Try for Free
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-001 Mar 26, 1999 DISCN Yes No ⤷  Try for Free ⤷  Try for Free
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 AP RX Yes Yes 9,968,659*PED ⤷  Try for Free Y ⤷  Try for Free
Novo Nordisk Inc INNOFEM estradiol TABLET;ORAL 040312-002 Nov 19, 1999 DISCN No No ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Novo Nordisk Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novo Nordisk Inc PRANDIMET metformin hydrochloride; repaglinide TABLET;ORAL 022386-001 Jun 23, 2008 RE37035 ⤷  Try for Free
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 6,004,297 ⤷  Try for Free
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 7,235,627 ⤷  Try for Free
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-002 Nov 25, 2009 7,018,992 ⤷  Try for Free
Novo Nordisk Inc VAGIFEM estradiol TABLET;VAGINAL 020908-002 Nov 25, 2009 5,860,946 ⤷  Try for Free
Novo Nordisk Inc VICTOZA liraglutide SOLUTION;SUBCUTANEOUS 022341-001 Jan 25, 2010 RE41956*PED ⤷  Try for Free
Novo Nordisk Inc PRANDIMET metformin hydrochloride; repaglinide TABLET;ORAL 022386-002 Jun 23, 2008 RE37035 ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for NOVO NORDISK INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 1 mg/500 mg and 2 mg/500 mg ➤ Subscribe 2009-04-09
➤ Subscribe Injection 18 mg/3 mL prefilled syringe ➤ Subscribe 2016-12-12
➤ Subscribe Vaginal Tablets 10 mcg ➤ Subscribe 2013-01-02

Supplementary Protection Certificates for Novo Nordisk Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2498758 PA2020003 Lithuania ⤷  Try for Free PRODUCT NAME: METFORMINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; SAKSAGLIPTINAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA; DAPAGLIFLOZINAS ARBA FARMACINIU POZIURIU PRIIMTINAS JO SOLVATAS; REGISTRATION NO/DATE: EU/1/19/1401 20191111
0770388 PA2009004 Lithuania ⤷  Try for Free PRODUCT NAME: ESTRADIOLI VALERAS + DIENOGESTUM; NAT. REGISTRATION NO/DATE: LT/1/09/1512/001, 2009 04 06 LT/1/09/1512/002, 2009 04 06 LT/1/09/1512/003 20090406; FIRST REGISTRATION: BE 327792 20081103
2498758 16/2020 Austria ⤷  Try for Free PRODUCT NAME: METFORMIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; SAXAGLIPTIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; DAPAGLIFLOZIN ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/19/1401 (MITTEILUNG) 20191113
1214076 C01214076/01 Switzerland ⤷  Try for Free PRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
2209800 1490067-4 Sweden ⤷  Try for Free PRODUCT NAME: COMBINATION OF INSULIN DEGLUDEC AND LIRAGLUTIDE; REG. NO/DATE: EU/1/14/974 20140918
0398460 04C0022 France ⤷  Try for Free PRODUCT NAME: ESTRADIOL ANHYDRE DROSPIRENONE; REGISTRATION NO/DATE IN FRANCE: NL 28661 DU 20040316; REGISTRATION NO/DATE AT EEC: RVG 27505 DU 20021211
2782584 C202130068 Spain ⤷  Try for Free PRODUCT NAME: COMPOSICION QUE CONTIENE ESTRADIOL (17BETA-ESTRADIOL), INCLUYENDO EN FORMA DE HEMIHIDRATO, Y PROGESTERONA; NATIONAL AUTHORISATION NUMBER: 85988-NL/H/4994/001/DC; DATE OF AUTHORISATION: 20210528; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): BE582231; DATE OF FIRST AUTHORISATION IN EEA: 20210406
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Novo Nordisk Inc Market Analysis and Financial Projection

Pharmaceutical Competitive Landscape Analysis: Novo Nordisk Inc – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Novo Nordisk stands out as a formidable player, particularly in the diabetes care and obesity treatment sectors. As we delve into the competitive landscape surrounding this Danish pharmaceutical titan, we'll explore its market position, strengths, and strategic insights that have propelled it to the forefront of the industry.

The Rise of a Pharmaceutical Giant

Novo Nordisk's journey to becoming Europe's largest company by market capitalization is nothing short of remarkable. With a staggering 430% surge in its stock price over the past five years, the company's valuation has soared beyond $600 billion, surpassing even the GDP of its home country, Denmark[5]. This meteoric rise can be largely attributed to the success of its groundbreaking drugs, Ozempic and Wegovy, which have revolutionized the treatment of diabetes and obesity.

"Novo Nordisk is no longer seen merely as a diabetes care company; it is now a dominant global leader in addressing one of the world's most pervasive health issues."[5]

Market Leadership in Diabetes Care

Novo Nordisk has firmly established itself as the global leader in diabetes care, commanding a significant market share. As of 2024, the company maintains its diabetes value market leadership with an unchanged market share of 33.7% compared to the previous year[3]. This achievement surpasses their strategic aspiration for 2025 of capturing more than one-third of the global diabetes market value.

GLP-1 Dominance

In the rapidly growing GLP-1 (Glucagon-Like Peptide-1) segment, Novo Nordisk's position is even more dominant:

  • Global market leader with a 55.1% value market share in the GLP-1 diabetes segment[3]
  • 63% volume market share in the overall GLP-1 market across diabetes and obesity treatments[3]
  • Nearly tripled its global GLP-1 patient reach from approximately 4 million to 12 million over the past three years[3]

These figures underscore Novo Nordisk's commanding presence in one of the most innovative and fast-growing segments of the pharmaceutical industry.

Product Portfolio and Innovation

At the heart of Novo Nordisk's success lies its extensive portfolio of innovative products and treatments, particularly in insulin and GLP-1 receptor agonists. The company's product lineup includes over 100 offerings, with significant contributions from insulin products[6].

Revenue Breakdown (2022)

Product Type Number of Products Revenue
Insulin 18 DKK 155 billion
GLP-1 Receptor Agonists 6 DKK 22 billion
Total 24 DKK 177 billion

This diverse portfolio not only demonstrates Novo Nordisk's commitment to addressing various aspects of diabetes care but also highlights its ability to generate substantial revenue from its innovative treatments.

Research and Development: The Engine of Growth

Novo Nordisk's commitment to innovation is evident in its robust research and development pipeline. In 2022, the company invested approximately DKK 33 billion (around USD 4.9 billion) in R&D, representing 19% of its total revenue[6]. This significant investment underscores the company's dedication to advancing treatments for diabetes, obesity, and other endocrine disorders.

R&D Pipeline Highlights

  • Over 50 ongoing clinical trials related to diabetes and obesity therapies[6]
  • Focus on developing next-generation treatments and exploring new therapeutic areas
  • Continuous improvement of existing products to maintain competitive edge

Global Reach and Market Penetration

Novo Nordisk's influence extends far beyond its Danish roots. The company has established a strong global presence, marketing its products in 168 countries and employing more than 48,000 people worldwide[7]. This extensive reach allows Novo Nordisk to tap into diverse markets and adapt its strategies to local healthcare needs and regulations.

Key Markets

  1. United States: Accounts for approximately 48% of total sales (DKK 109.6 billion in 2022)[6]
  2. Europe: Significant presence across European markets
  3. Emerging Markets: Growing focus on expanding in high-growth potential regions

Competitive Advantages

Novo Nordisk's sustained success in the highly competitive pharmaceutical industry can be attributed to several key strengths:

1. Brand Recognition

As of 2023, Novo Nordisk holds a leading position in the global diabetes care market with a market share of approximately 28%[6]. This strong brand recognition is reflected in consumer healthcare surveys, indicating that over 70% of healthcare professionals consistently recommend Novo Nordisk products for diabetes management.

2. Manufacturing Capabilities

The company has made significant investments in scaling its production capacity to meet the growing demand for its GLP-1 products. Recent announcements include:

  • Total investments exceeding 130 billion DKK since 2021[3]
  • Completion of the Catalent transaction in December 2024, expanding Novo Nordisk's global fill-finish footprint from 11 to 14 sites[3]
  • Plans to build a new production plant in Clayton, North Carolina, at a cost of $4.1 billion[7]

These investments ensure that Novo Nordisk can maintain its market leadership position by meeting the increasing global demand for its products.

3. Financial Strength

Novo Nordisk's financial performance has been exceptional, with its market capitalization now exceeding the GDP of Denmark[7]. This financial strength provides the company with the resources to invest in R&D, expand manufacturing capabilities, and pursue strategic acquisitions.

4. Corporate Culture and Leadership

The company's commitment to its corporate culture, known as the Novo Nordisk Way, has been crucial in managing its rapid growth. To maintain this culture while expanding, Novo Nordisk has implemented leadership development programs like NNX (Novo Nordisk Next) for senior executives[7].

Strategic Insights and Future Outlook

As Novo Nordisk continues to dominate the diabetes care and obesity treatment markets, several strategic insights emerge that will shape its future:

1. Expansion Beyond Diabetes

Novo Nordisk is broadening its focus from diabetes care to a more ambitious mission of "defeating serious chronic diseases"[7]. This strategic shift opens up new opportunities for growth and diversification.

2. Emerging Market Penetration

There's significant potential for Novo Nordisk to expand its presence in emerging markets where diabetes prevalence is rapidly increasing[4]. Tailoring products and strategies to these markets could drive substantial revenue growth.

3. Addressing Competitive Threats

While Novo Nordisk currently enjoys a strong position in the GLP-1 market, the landscape is becoming increasingly competitive. New entrants and existing competitors like Eli Lilly are developing similar treatments, necessitating continued innovation and strategic positioning[8].

4. Navigating Pricing Pressures

Changes in healthcare policies and regulations, particularly in key markets like the United States, may affect pricing and reimbursement for Novo Nordisk's products[6]. The company will need to navigate these challenges while maintaining profitability and market access.

5. Supply Chain Resilience

Given the potential for supply chain disruptions, as seen during the COVID-19 pandemic, Novo Nordisk must continue to invest in and optimize its global manufacturing and distribution networks[6].

Key Takeaways

  1. Novo Nordisk has established itself as the global leader in diabetes care, with a particularly dominant position in the GLP-1 market.
  2. The company's success is driven by its innovative product portfolio, substantial R&D investments, and strong brand recognition.
  3. Significant investments in manufacturing capabilities position Novo Nordisk to meet growing global demand for its products.
  4. Strategic expansion beyond diabetes care into broader chronic disease management presents opportunities for future growth.
  5. Navigating competitive threats, pricing pressures, and potential supply chain disruptions will be crucial for maintaining market leadership.

FAQs

  1. Q: What is Novo Nordisk's market share in the global diabetes care market? A: As of 2024, Novo Nordisk maintains a 33.7% value market share in the global diabetes care market.

  2. Q: How has Novo Nordisk's stock performance been in recent years? A: Novo Nordisk's stock price has surged by approximately 430% over the past five years, leading to a market valuation exceeding $600 billion.

  3. Q: What are Novo Nordisk's key products in diabetes and obesity treatment? A: Novo Nordisk's key products include Ozempic and Wegovy, both based on the active ingredient semaglutide, which have revolutionized diabetes and obesity treatment.

  4. Q: How much does Novo Nordisk invest in Research and Development? A: In 2022, Novo Nordisk invested approximately DKK 33 billion (around USD 4.9 billion) in R&D, representing 19% of its total revenue.

  5. Q: What strategic challenges does Novo Nordisk face in the coming years? A: Key challenges include increasing competition in the GLP-1 market, navigating pricing pressures, expanding in emerging markets, and maintaining supply chain resilience.

Sources cited: [3] https://www.novonordisk.com/content/dam/nncorp/global/en/investors/irmaterial/annual_report/2025/q4-2024-investor-presentation.pdf [4] https://pitchgrade.com/companies/novo-nordisk [5] https://quartr.com/insights/company-research/novo-nordisk-the-danish-pharmaceutical-titan-revolutionizing-global-healthcare [6] https://canvasbusinessmodel.com/products/novo-nordisk-swot-analysis [7] https://en.wikipedia.org/wiki/Novo_Nordisk [8] https://www.investing.com/news/swot-analysis/novo-nordisks-swot-analysis-stock-outlook-amid-glp1-market-growth-93CH-3838627

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.